What is Quoin Pharmaceuticals Financial Strength?
Quoin Pharmaceuticals has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Quoin Pharmaceuticals Ltd shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Quoin Pharmaceuticals has no long-term debt (1).
As of today, Quoin Pharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Quoin Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Quoin Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quoin Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Quoin Pharmaceuticals's Financial Strength falls into.
Quoin Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Quoin Pharmaceuticals's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-2.46 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Quoin Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
| Quoin Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Quoin Pharmaceuticals Ltd has no debt.
2. Debt to revenue ratio. The lower, the better.
Quoin Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Quoin Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
| Dennis Langer |
director |
C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103 |
| Michael T Sember |
director |
AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101 |
| Joseph Patrick Cooper |
director |
PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103 |
| Anthony James Culverwell |
director |
C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101 |
| Gordon Dunn |
officer: Chief Financial Officer |
AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101 |
| Denise P. Carter |
director, officer: Chief Operating Officer |
AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101 |
| Leong Natalie Ee Mun |
director |
AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101 |
| Michael Myers |
director, officer: Chief Executive Officer |
AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101 |
Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QNRX has been successfully added to your